CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 126 enrolled
Drug / intervention
N-acetylcysteine +1 moredrug
Likely dose
N-acetylcysteine 1200 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03707951
NCT03707951Phase 2Completed
CompareCT.gov

A Proof-of-Concept Trial of N-Acetylcysteine for Adolescent Alcohol Use Disorder

Medical University of South Carolina·interventional·Posted Oct 16, 2018·Updated Jan 8, 2025

In Brief

A Phase 2 clinical trial evaluating N-acetylcysteine and Placebo oral capsule for Alcohol Use Disorder. Completed, enrolled 126 participants across 1 site.

Detailed Summary

This is a 8-week randomized, placebo-controlled trial testing the effects of N-acetylcysteine (NAC), on a platform of weekly evidence-based brief alcohol intervention for 120 adolescents with alcohol use disorder (AUD). The primary efficacy endpoint is reduction in alcohol use (total standard drinks), compared between NAC and placebo groups.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlcohol Use Disorder
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedOct 16, 2018
Enrollment StartFeb 27, 2019
Primary CompletionFeb 26, 2024
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 7.7 years ago

Interventions

N-acetylcysteinedrug

N-acetylcysteine 1200 mg twice daily for 8 weeks (administered orally)

Placebo oral capsuledrug

Placebo (matched in appearance to N-acetylcysteine to preserve double-blind) twice daily for 12 weeks (administered orally)